Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Forte Biosciences, Inc./ 10-Q

Quarterly Report · 10-Q

Forte Biosciences, Inc.

Quarterly Report

Filed Aug 12, 2026Accepted Aug 12, 2026, 4:01 PM EDTCIK 1419041Accession 0001193125-26-346787
View company →Permanent SEC source ↗
Share

Company context

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Historical securities (1)
FBRXNASDAQ · EQUITY · Historical · closed Aug 27, 2026

Recent company filings

  1. 15-12G filingSep 8, 2026
  2. 15-12G filingSep 8, 2026
  3. 15-12G filingSep 8, 2026
  4. EFFECT filingSep 1, 2026
  5. EFFECT filingSep 1, 2026

Registered securities in this filing

FORTE BIOSCIENCES, INC. · 10-Q · Filed 2026-08-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
FBRX
Exchange
NASDAQ
Classification
COMMON
Status
Historical · closed Aug 27, 2026
Filing context

Context: C_4d74824a-e369-478d-b5d9-cd874d500d62

Dimensions: Not supplied

Accession 000119312526346787 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.